FL2022-001 Inc. has patented new 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for the treatment of liver fibrosis and nonalcoholic steatohepatitis.
Work at Praxis Precision Medicines Inc. has led to the identification of new compounds comprising an azaspiroheptane and acting as T-type calcium channel blockers, particularly voltage-dependent T-type calcium channel subunit α-1G (Cav3.1) blockers. As such, they are reported to be useful for the treatment of essential tremor.
Inhibitors of diacylglycerol kinase, particularly diacylglycerol kinase α (DGK-α, DGKA) and/or diacylglycerol kinase ζ (DGK-ζ, DGKZ), believed to be useful for the treatment of cancer and viral infections, have been disclosed by Inventisbio Co. Ltd. and Inventisbio LLC.
Carboexpert Inc. has identified compounds acting as interleukin-1β (IL-1β), interleukin-8 (IL-8; CXCL8) and TNF-α production inhibitors reported to be useful for the treatment of allergy, sepsis and inflammation.
An Oncolinea Pharmaceuticals Inc. patent describes nucleosides acting as DNA repair inhibitors and thus reported to be useful for the treatment of cancer.
A team at the University of Geneva has developed prodrugs of antimicrobial agents and particularly conjugates comprising antimicrobial agents covalently bound to a tocopheryl or tocotrienyl group through a linker with micelle formation ability and improved stability.
Sanofi SA has prepared and tested pyrazolopyrazinone compounds acting as cystine/glutamate transporter (solute carrier family 7 member 11; SLC7A11; xCT) inhibitors.
Complement factor B (CFB) inhibitors are described in a Novartis AG patent and reported to be useful for the treatment of age-related macular degeneration, diabetic retinopathy and eye disorders, among others.
RSS